Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Analysts at Canaccord Genuity

Canaccord Genuity started coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report released on Monday, BenzingaRatingsTable reports. The firm issued a buy rating and a $44.00 target price on the stock.

STOK has been the topic of a number of other research reports. JPMorgan Chase & Co. restated a sell rating and issued a $18.00 target price on shares of ABB in a research note on Monday. Cowen restated a buy rating on shares of Avrobio in a research note on Monday.

Shares of Stoke Therapeutics stock opened at $23.89 on Monday. Stoke Therapeutics has a 1 year low of $22.84 and a 1 year high of $31.76.

In related news, major shareholder Rtw Investments, Lp bought 555,556 shares of the business’s stock in a transaction dated Wednesday, June 19th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $10,000,008.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Apple Tree Partners Iv, L.P. bought 1,388,889 shares of the business’s stock in a transaction dated Friday, June 21st. The stock was bought at an average price of $18.00 per share, for a total transaction of $25,000,002.00. The disclosure for this purchase can be found here.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Recommended Story: How do candlesticks reflect price movement?

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.